BioTuesdays

Category - Markets

Viking Therapeutics Logo
Markets

WB starts Viking Therapeutics at OP

William Blair launched coverage of Viking Therapeutics (NASDAQ:VKTX) with an “outperform” rating. The stock closed at $3.97 on April 27. Viking has a differentiated clinical pipeline focusing on modulating hormone...

April 30, 2018
Dova Pharmaceuticals
Markets

Ladenburg starts Dova Pharma at buy; PT $65

Ladenburg Thalmann initiated coverage of Dova Pharmaceuticals (NASDAQ:DOVA) with a “buy” rating and $65 price target. The stock was quoted at $26.55 near the close on April 26. Dova is focused on the development and...

April 26, 2018
Prothena
Markets

BTIG cuts Prothena to neutral; discontinues PT

BTIG downgraded Prothena (NASDAQ:PRTA) to “neutral” without a price target after the company discontinued development of NEOD001, an investigational antibody being evaluated to treat AL amyloidosis. The stock dropped...

April 24, 2018
Cipher Pharmaceuticals
Markets

Mackie cuts Cipher Pharma PT to $5.30 from $7.10

Mackie Research Capital lowered its price target for Cipher Pharmaceuticals (TSX:CPH) to $5.30 from $7.10 after the company lowered first quarter expectations on the back of weak Absorica sales. Analyst Andre Uddin...

April 24, 2018
Homology Logo
Markets

BTIG starts Homology Medicines at buy; PT $35

BTIG initiated coverage of Homology Medicines (NASDAQ:FIXX) with a “buy” rating and $35 price target. The stock closed at $19.90 on April 23. Founded in 2015, Homology is a genetic medicine company that is focused on...

April 24, 2018
Matinas Biopharma
Markets

Maxim cuts Matinas BioPharma PT to $4 from $6

Maxim Group lowered its price target for Matinas BioPharma (NYSE American:MTNB) to $4 from $6, citing dilution from the company’s next financing. The stock closed at 68 cents on April 20. Analyst Jason McCarthy writes...

April 23, 2018
Knight Therapeutics
Markets

RBC starts Knight Therapeutics at OP; PT $9.50

RBC Capital Markets launched coverage of Knight Therapeutics (TSX:GUD) with an “outperform” rating and price target of $9.50. The stock closed at $7.79 on April 20. Knight’s focus is on the licensing and...

April 23, 2018
Ovid Therapeutics
Markets

Ladenburg starts Ovid Therapeutics at buy; PT $27

Ladenburg Thalmann initiated coverage of Ovid Therapeutics (NASDAQ:OVID) with a “buy” rating and $27 price target. The stock closed at $10.14 on April 19. Ovid is developing two clinical-stage candidates: OV101, a GABA...

April 20, 2018
Sientra Logo
Markets

Leerink resumes coverage of Sientra at OP; PT $19

Leerink resumed coverage of Sientra (NASDAQ:SIEN) with an “outperform” rating and $19 price target. The stock closed at $11.98 on April 19. Leerink suspended coverage of Sientra in 2015 following a CE Mark suspension...

April 20, 2018